Alternative Data for Bio-Techne
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 115 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 148,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,828 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,595 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 687 | Sign up | Sign up | Sign up |
| X Followers | 2,341 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 3,250 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 43 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,958 | Sign up | Sign up | Sign up |
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.
| Price | $70.93 |
| Target Price | Sign up |
| Volume | 1,000,000 |
| Market Cap | $10.7B |
| Year Range | $46.53 - $70.93 |
| Dividend Yield | 0.46% |
| PE Ratio | 140.14 |
| Analyst Rating | 71% buy |
| Industry | Biotechnology |
In the news
 |
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial ResultsJanuary 19 - Yahoo |
 |
Bio-Techne Corporation (TECH) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 12 - SeekingAlpha |
|
Here's What to Expect From Bio-Techne's Next Earnings ReportJanuary 8 - Yahoo |
|
A Look At Bio-Techne (TECH) Valuation After Analyst Downgrade And Softer Cash Flow ConcernsJanuary 8 - Yahoo |
 |
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?January 7 - SeekingAlpha |
 |
Maryland Rep. April McClain Delaney Bought Up to $135K Worth of Bio-Techne StockJanuary 6 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 287M | 96M | 190M | 38M | 78M | 0.420 |
| Q2 '25 | 317M | 118M | 199M | -18M | 6.4M | 0.530 |
| Q1 '25 | 316M | 102M | 215M | 23M | 68M | 0.560 |
| Q4 '24 | 297M | 103M | 194M | 35M | 72M | 0.420 |
| Q3 '24 | 289M | 106M | 183M | 34M | 70M | 0.420 |
Insider Transactions View All
| BAUMGARTNER ROBERT V filed to sell 44,863 shares at $56.2. August 27 '25 |
| Nusse Roeland filed to sell 44,559 shares at $56.4. August 27 '25 |
| Herr Amy E. filed to sell 1,976 shares at $49.8. June 11 '25 |
| Herr Amy E. filed to sell 1,976 shares at $66. February 18 '25 |
| Kelderman Kim filed to sell 39,004 shares at $78. January 29 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| April Delaney |
Jan 6, 26 | Buy | $1K - $15K |
| April Delaney |
Jan 6, 26 | Buy | $1K - $15K |
| April Delaney |
Nov 5, 25 | Buy | $1K - $15K |
Read more about Bio-Techne (TECH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Bio-Techne
The Market Cap of Bio-Techne is $10.7B.
As of today, Bio-Techne's PE (Price to Earnings) ratio is 140.14.
Currently, the price of one share of Bio-Techne stock is $70.93.
The TECH stock price chart above provides a comprehensive visual representation of Bio-Techne's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bio-Techne shares. Our platform offers an up-to-date TECH stock price chart, along with technical data analysis and alternative data insights.
Yes, Bio-Techne (TECH) offers dividends to its shareholders, with a dividend yield of 0.46%. This dividend yield represents Bio-Techne's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Bio-Techne in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Bio-Techne are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
